CRBP - Earnings call transcript Q2 2020 | Corbus Pharmaceuticals Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello and welcome to the Corbus Pharmaceuticals Second Quarter August 6th 2020 Earnings Conference Call.

As a reminder, all participants are in a listen-only mode. [Operator Instructions] This conference is being recorded at the Company’s request and will be available on the Company’s website following the end of the call. I will now turn the conference over to your host, Ted Jenkins, Senior Director, Investor Relations and Corporate Communications. Please go ahead, sir.

Ted Jenkins

Brock. you, Thank everyone. Good morning time, remarks I’d intentions, our this future. to beliefs, like during this that the made for management’s or listeners call expectations, At projections remind may hopes, state and are involve These statements risks uncertainties. and forward-looking

pursuant and Forward-looking Harbor the differ actual laws. forward-looking results provisions are on based securities Safe statements federal could to are statements the Corbus' call on These this made of current materially. expectations

not should a undue on any you statements. As forward-looking reliance place result,

results the encourage to are are and materially in Securities files factors contemplated that of Exchange such of the These Corbus available website. actual by documents cause Some carefully. to Investors the section those and Commission’s differ the could reports you documents Exchange these the Commission. Securities from review website forward-looking Company’s discussed on We in with statements the periodic and

Dr. Moran, the Officer; Research; Officer my on Sean today it Dr. call Chief Yuval. Millian, is Financial the over Commercial Officer. White, pleasure our to me and our Barbara Executive With call Joining Cohen, Medical that, our and Officer; Chief are turn our Craig to Chief of Chief Head Yuval

Yuval Cohen

Good is to everyone of my Corbus everyone. you, welcome quarter morning call. XXXX Pharmaceuticals pleasure second conference Thank to earnings Ted. It

very second Our team has had a busy quarter.

what We transformative year are in could believe months. for on with the track be we multiple coming anticipated catalysts

top-line our concluded recently from Phase to sclerosis data summer. look study systemic forward this First, we X

our followed will in results these cystic by third be concluded the Xb fibrosis Next, results recently Phase quarter. study

the and announced raised this than flexibility finances FDA ahead ground work stronger pressure ATM the without a overhang. more ever our financing than strategic then significant we ability to submission focusing investment, strategy the capital a more additional readouts are have of having and financing of on closer now With NDA potential time, KX preparing from This we’ve to from just debt capital following data and HealthVentures. gives approval. commercialization following of data deal $XXX our that of ever, these combination data a critical At for million up are us

on research very and also new us significant the to are of will from White Dr. companies our Board George’s Officer growing drug system. advancing Dr. a Medical Research, transition comments I Golumbeski the Corbus join programs We now over Officer. as of with George us and Barbara. a candidates Millian, endocannabinoid will commercial-stage to be Board turn pipeline Barbara innovation a R&D-only to call deep of Member experience to followed Craig you, to asset and Thank an our be our Head organization clinical we Chief a pleased Directors. an update by novel provide targeting with Commercial on company Chief have to our from

Barbara White

reviewing impact Thank Phase substantially you, patient, Yuval. not in start to the I by CF last or COVID-XX of would last delay on programs. the the our clinical like X study did RESOLVE study. Xb visit COVID-XX

database However, slowed time to it has lock.

of data, sites negative own of consequences activities of restrictions ability the use data. These these alternative and and access RESOLVE data, shut that study. and over to sites remains essentially To access study CFXXX at and study to usually in-person data we up and is study entry changes staff COVID-XX to assessments a some anticipating priority subjects, and remote and to physical the potential lock done and three COVID-XX-associated data questions end of these site monitor followed completion central the database studies responding set Similarly, from the the In-person Xb data For of study X restricted other Combined and sites data site Phase monitoring. even to and responses X about access staff entry SSc and the study on study sites are was continue for down adjust to data Phase near ways monitoring the to to systemic Phase took integrity staff temporarily. was cleaning CF studies. the top-line closed about months slowed have their soon and limited. data do data. hence and of for data study to limitations X by CFXXX sclerosis be we Phase expecting X Xb limited that top-line slowed and Nonetheless, for are Phase

greater In We RESOLVE equal subject slowed rate or for studies Last are than at limitations addition, than X Phase start which those in Phase the primary study, study at powered assumed May study. XX or some discontinuation week RESOLVE than completed data is vendors study double-blind at to Data SScXXX is of and and XXX COVID-XX-associated X although XXX entry early, in expected that the ACR Of less the study XX% for estimate in efficacy X We the score X.XX lower subjects XX. remains XX. part at or we reported visit X is subjects the the start cleaning XX% be study ongoing. very dosed study. the the endpoint now the of the complete CRISS discontinued completed study XX% near-term. the was supported placebo-controlled the on dosed of

the COVID-XX. note, in open study of still already the least ongoing, subjects the X% or of completed is X and XX% first label open out subjects of X subjects and report of during OLE. extension were year is study mark extension, study. which to at open database given have SSc-XXX on dropped which XX% XX extension for analyses. of find from XX of separate Phase the Of this label subjects year coming XXX of label X SSc-XXX data the extra eligible X.X visits open X XXX are Only or label RESOLVE encouraging SSc schedule of the the the subjects the top-line in XX lock the six study, following the open or extension data The to-date, Phase at entered burden we summer the in extension We Phase have label

score new quarter, ACR study and improvements World feel the and X presented Systemic Phase analysis patients CRISS function correlates E-Congress. from from at This Sclerosis how baseline were the lenabasum showing SSc with Xth

effects data EULAR of may showing were the of addition, the In inhibition Conference. include biologic Annual at lenabasum inflammasome activation presented

Japan’s in for also for Kaken medical PMDA. sclerosis are pleased We and of orphan Agency or drug to Pharmaceutical systemic the announce Pharmaceuticals, partner our designation that recently Japan from Devices lenabasum obtained treatment

completed remains early. extension have study. XX of This the To-date, or for We this nearly first less study or from Turning of the study to X% XXX Xb weeks study XX. Last to X.XX. subject XXX Phase study, the subjects and Data are entry was discontinued had this dosed and than in X subjects visit those, we DETERMINE lenabasum on dermatomyositis XXX open subjects the XX% only June is CF-XXX reported at label subjects. which target CF-XXX X% visit study which of dosed early a Phase of occurred. in enrolment Yesterday, or of equal actively we the last about rate complete the than rate data. for exacerbations or The that event at study from our patient exceeds cleaning the XX of with X study discontinued lower XX% unchanged the P reported XXX start is of for again at discontinuation assumed we Power the pulmonary CF-XXX study going study. abnormalities enrollment sponsored was The this in fibrosis have Corbus subjects and to-date. at exposure. we to growing. several study. measure enrolled X pipeline the by programs subjects at in been NIH of about and CRB-XXXX NIH year. studies end that lupus of hundred in because study which halted studies Phase study undergoing inverse preclinical year be ongoing. primates several pharmacokinetic I temporarily is these the are by now. optimistic is are agonist, systemic lenabasum speak label sites. subjects CRB-XXXXis disease. but XX enrolment CDX metabolic of briefly expected recently the models note, of to-date XX% reduces a COVID-XX, X and is of patient chronic Of in in all is Study may year. improves complete the or to this active non-clinical and of mark Results brain XX inflammation has still Phase erythematosus am resumed were open eligible enrolled XX extension, the three DM-XXX have of had

R&D our As CRB-XXX one our CDX last promising remember agonist that Day, from may is in-house. you of has developed Corbus

announce selectivity for are Non-clinical pleased We significant for biologic studies has to IND activity and that inflammation models next enable to and CDX are and fibrosis. of development and our underway. animal formulation selected on as work submission based candidate and potency CRB-XXX its been

X We expect safety CRB-XXX XXXX. be testing to Phase in in

Craig will update. will Millian, next our commercial at you the with information the share call to R&D now I turn will over provide program Day. We who

Craig Millian

morning. Thanks, Barbara. Good

top-line to We be and commercialization lenabasum. data the toward are anticipated very of excited closer moving

to market we our leadership execute medical making build Over the a and for brief the we the second on progress efforts. teams out today affairs, I are operations key our support With launch. on commercial disease scaling provide in effectively education am in successful launch going quarter, our updates our to of areas as on place access, as to well prelaunch we key up continued marketing, team, to plans are and advancing activities

of area to market model. field medical implementing go first our focus The is

of ahead in disease The at ensure will field scientific national relationships approach studying, are number small reporting data. we a as for part the a presence will of would strong up scientific programs. with both science or are related appropriate states leaders building team medical the to clinical hiring will We are information responsible be executing affairs and They of Liaisons a as that clinical be MSLs, MSLs the experts phased and regional external and Barbara. clinical with initial positive to launch well level. follow medical MSLs robust which of the and medical medical our

market accounts, scaling plan commercial including as further areas also patient reimbursement, following analytics. national other providing additional future services We in technology, key these to capabilities to and and we look payer build data. calls details launch-related marketing, forward begin I up

highlighted Turning education unique fully we Data. disease this total visitors. who we more the expanded and previous campaign. out to continuing SSc the systemic of XX,XXX are recently, to by Earlier program. are briefly website leverage to rollout Acclaim traffic rheumatologists the And majority and outreach as on call, More to we has The we campaign making treat this EL our disease identified directed our total disease steadily education. targeted launched I received this build progress On with of education the increased ssc.com year, the sclerosis an to-date, than campaign month-over-month. physicians website

year. to we total and plan other content are subject to matter, including website key with this later in dynamic SSc collaborating further the on and expand educational leaders sclerosis have systemic the We opinion actively available videos

unmet strong Sclerosis burden a Corbus this engaged position had were Corbus to the were the to presence a in learn at option mentioned, organizers our progress We commercialize to over and of the booth make In SSc FDA on the substantial turn portion months at Systemic campaign to be to of coming forward Barbara that Yuval. promise meeting our registrants in We and efforts now total following to fully and continue agonism. suffering total the CDX from sclerosis, ensuring the E-Congress. with educate leveraged we back and need important visited large debilitating you there on summary, with will pleased and booth disease. drive update look patients conference treatment lenabasum, content. As and to call to engagement I the Virtual providing successfully key the World approval the to expanding systemic Virtual to continuing we X,XXX will

Yuval Cohen

Thank you, Craig.

update these capital, approximately strong of the to KX our will an in $XX Craig. provide data. cash XX, reported ATM in We us and $X and head and our we July milestones. excited for payment reiterate I XXXX from the million million us would $XX $XX HealthVentures, from is facility with new financing whom a Sorry. of of closing, hand like Fibrosis to million We balance strategic towards we flexibility putting tranche. Barbara received sheet. to a first into as recently giving valuable Thank announcements of $XXX on announced financial strong debt million are existing also very We’ve I Cystic $XXX are a on We you, million in position. million now grateful. our data financial with heading In up upcoming which how milestone position comprise Foundation

R&D-only of the and time call change to an you open our We commercial-stage organization the and are for the believe this Thank the all operator and on inflection are to from your questions that a turn data from back poised point. an these company. our We attention verge transition call morning. will audience. for we’ll to company make I we upcoming now the

Operator

from Capital [Operator RBC Instructions] Abrahams with comes of proceed Brian Our question question. first today Markets. your Please

Brian Abrahams

there. the the I I I on am details and questions. trends out predicated Congrats presentation, Hi any the FDA morning. across how for patient as taking wondering progress CRISS on of all viewing and CRISS. approval are detailed Thanks and on to trials. – benefits one enrollment regulatory CRISS PROs recent coming on the guess, the or appreciate reported to sense mRSS? amenability of the my clinical KOLs primarily overall all to, I on as Good guess, the guess, really if well in are my versus components is the the outcome first timelines

Barbara White

very your Thanks for Barbara. much is This Brian. question. Hi,

based thinking they on belief score towards has has mRSS, happened moved in thickening discussed perhaps I not think in opinion and in change sclerosis. clinical as in what that while thinking this in clinical five sclerosis. at impact of is to the world outcome systemic my hasn’t swung time. in modified performed a about sought the And uses valuable clinical in assessment at to skin or have those holistic trials mind, around ACR we’ve KOL And towards score systemic experts past before, most have Rodnan that approach that by the trials, trials we composite important disease. a the is more efficacy in It performing well outcome skin primary CRISS especially as assess especially, best it a treatment that at looking with of be the measures overall are on

drugs. this looking do KOL approach of in time, study improvement think supportive patients at at on in at So, general this we opinion that, is holistic

look was We as that and stressed FDA think of efficacy told ACR CRISS We terms In to with us. reasons quite also primary we’ve the of been the that agency us why, benefits. views, patient CRISS are that score evaluating totality has the regulatory at we most ACR include They of they with the considered you to outcomes, experts not the chosen have I but want data. in to endpoint before, its the and to five components choice the to by patients of said the – overall clear that the believe they just be status essential reported will speak treatment assessment. will on will effect contribute and said, I as lung effect the reasonable expectation. way on score skin, a that’s all works global contribute. the certainly is physician The up All

to expect So, which and with we how be does to important to score that show correlate patients function the be feel regulators. will the able

Brian Abrahams

systemic file what really the then, to That’s it. Thanks. in you Got additional work And to do helpful, all need the NDA sclerosis Barbara. following data.

and could supportive and impact that? if COVID filing how Phase a I you data the think potential mentioned talk potentially curious timelines I bit you additional some Xwork little more about am between and could

Barbara White

that meeting. pre-NDA with to this is are filing end move happen on all X some not and NDA. Well, hear, of next – will will the NDA with that based delay of we what and that, step anticipating we year. they complete actually books studies the as we or believe are point have they do filing. study we there and are and underway. the I And studies impairments will and step have important to Most TQT do at They are, that the we renal with the we’ll and then, Phase hepatic the getting NDA forward And underway mentioned, the I at to we think that filing

are next course think, terms NDA I happening itself. the FDA year, I of rather anticipating timelines, of from but filing, have we’d really again, input we in until we prefer think wait the So, to

Brian Abrahams

It me from One could. one makes if sense. last I

over cleaning the lot some and headwinds You the the when data analysis comes weeks. through potential managing spoke a about of few to COVID-related past it

relative Now pandemic expectations from guess, imputation what I you guys had last so Thanks standpoint? you to, overall analysis about missing collection well, statistical going managing last in impact can are through as on the that anticipated also much. and the how the talk visit, and that data through for data you – of patient, a

Barbara White

for one Brian Thanks, too. that Sure.

assessments. able were thought and in statistical analysis doing we FDA patients more plan did to came study, safety how on has what done who anticipated. in all, When because be remain for say, First with, consistent doing with in can than the XX. thing. that There We it X most XX% outs that these were essentially we’ve on end remotely all have very start we two as because board would some than to of we The were CRISS had is SSc had across we efficacy at Phase and enrolled that most were to visits the powered that still really issued the handle the are ACR guidance patients, critical assess the less and more at true of and, well than held studies the and that’s not for our done were patients are last some we the and nearly powered out. patients all we the we drop I week in we we

the few them is powering. a substantial a study So, at it’s statistical assessed is difference are the analysis across variability yes, the thing we assessments repeated the measures. other not way using but our make small in enough lost done, And end, make to the with

our with helps also that So powering.

despite was actually done safety very primary of could of the all on was so it beginning done set assessment an terms case, done the on the the study, pulmonary because that endpoint exacerbation. CF occurrence In patients. be was of patients from the all on COVID-XX, remotely up In efficacy again this

So, didn’t any primary at efficacy in the lose endpoint in the all from study. we data it CF

was phases in The in the early some the delay will with impact and Phase we impact again well at expect or bigger the of data this it substantial remains again, start studies So, on that there. the point. powering the powered. largely Dermatomyositis which start a X

Brian Abrahams

again data. super to looking forward Got That’s the helpful. it. Thanks and

Barbara White

Thanks.

are too. We

Operator

is question The next of Jefferies. Raycroft your proceed Please question. from with Maury

Maury Raycroft

on morning taking for my everyone. the Congrats progress questions. Good and Hi. thanks

one have I So, SSc. on

stats wondering function So one in you am specific on FDA need hit I FDC there regarding indicated have previously your guidance in has guys real is I mRSS. present mentioned you guess, any that are that commercial and who mind strategies are there for have? thoughts guys or what natural setting worsening a that FDC. combo world any patients in are if you

Barbara White

Barbara. is this Maury,

I very of the didn’t hear part I quite think last the question.

So, mind ahead. would sure that repeating I make you to go before do. want we I

Maury Raycroft

Sure.

for Just thoughts that? the natural you for in strategies setting wondering patients guys real and commercial on FCC have are if mind or with treating there world worsening combo

Barbara White

Okay.

take and the take I’ll first will So, second. part Craig the

line. to study I the selection the which year, much lenabasum So, endpoint. in patients. predicted who decline to time. may our in particular at we is than over patients in that’s right probably Nonetheless, course less the in anticipate decline that the that XX%, larger statistical and anticipate X That than in secondary lenabasum point our the group and would in at The is not the several What for baseline Phase X.X% in reduction greater the requires over we placebo seeing The of placebo third patients terms just risk from out see to of treated treated in of a SCC. the treated about percent percent that be is expect a history X% natural SCC, SCC points study percentage SCC predicted border powered seeing we is less baseline SCC study patients. is, the difference want in

as If individual, disease. have less you to that to considered you have lung considered an than interstitial could have be can XX% predicted – be

have study that will Craig? see to do substantial that lung very involvement. significant And patients we we expect expect in unmet So address the indeed an our and impact a do need.

Craig Millian

a Yes. comments. few just And

with meaningful of XX% interstitial system about lung patients of some clinically XX% to disease. sclerosis diffuse the So, have

on a system lung component many that the so expect, stable treating sclerosis that’s all whom problematic. that And used priority patients to elements are know to are that our would in treat would of their trial, a as – decline we Barbara for physicians sclerosis. in described, We the are part treat based that of be immunosuppresssion systemic other the complementary of already in we fashion on

about components So, what data the this patient a see Pharmacy tell to again, we view Holly we the us lenabasum, patients other the view armamentarium of systemic addition data sclerosis. we’ll who on these favorable, will a certainly segmentation, as are and view in certainly terms should the troubling for population of if potentially be patients think we that be it for diffused helpful of we

Maury Raycroft

is very That’s if then follow-up investigators SSC impacted the dermatomyositis investigator can whether of sites and and you this am are wondering as the And in over-enrollment there investigators I it. and in skin Got And the what about just a as SSC? in question, was seeing involvement helpful. between the overlap that by enthusiasm given anything dermatomyositis SSC, on studies. comment

Barbara White

are question. overlap and characterized and Barbara. This both the manifestations Thank some for by have certainly Maury some substantial is diseases inflammation tissue damage. and degree clinical chronic is overlap. The disease There themselves you, again of

academic We sites. the are

we the top world at are We looking at sites and rheumatology. in rare around diseases are

So overlap. that towards certainly lens

had with and In investigators sites addition, experience these we’ve SSCs. and

more feel study comfortable that comfortable feel think actually and So there the pluses with same using us to of the sites. allows operational some we then real to is that by more DM

was going over-enrollment I didn’t trouble of smaller it much what rewarding. studies. have us, Others the be the really in terms to like. enrolling to study, the DM in We think had quite been, know enrollment has that

that but even characteristics that much began in to well much does just think speak But need. slowed a patients as it – you have to, and presented and slowed. most very of joint the It very least other when as global enrolling disease mean, powering are started, But the And reopen told in they physicians, study we to quickly more to skin people more. we got muscle purposes. and at are we’ve hey, DM first when of COVID-XX, agents. got them enrolled foremost have unmet get They’ve for in mid easily weakness. again told our we it we This than advisors more that thought. organs in fit. – skin the mean. a part, they background are baseline getting And all have patients patients, it and them The and and throes early kept of KOLs certainly significant Our COVID-XX, assessments They which is I significant still less in range are and a time involvement, They sites more the the have to immunosuppressive. it enroll going tough many our turn us, wanted at are than immunomodulating us quickly. are lung could thought. COVID-XX pretty also during study that We started XXX. I upfront, are enrolled on immunosuppressants, going in during involvement and

I over-enrollment. are these of that enthusiasm think unmet substantial very group with need to part in speaks So patients a the and

to over that. enroll. also they that subjects already I’ll do we we’d to had are like the But with our have ability course, Of and had investigators something in with experience had first experience stop to with the the speed think optimistic. that and

Maury Raycroft

exact of know overlap two perspective. in sites Great. the number you guess, between studies. I Great the

Barbara White

at – my that my have don’t at I fingertips. dispose

a give I of to So fair want incorrect wouldn’t information. But, number there them. you is

Maury Raycroft

Understood.

Thanks for Okay. questions. again taking my

Operator

your Gershell with Company. from proceed The & Oppenheimer next is question of Please question. Leland

Leland Gershell

for much very taking update you Thank for that questions. morning. and Good my comprehensive

me, to you that question that with will module as about sometime along RESOLVE should to Would should How said the should about we the after that dual the registrational decision, kind be about approach? go Presumably RESOLVE regulatory you want NDA we include application. approach the a Thank the How in think data, serve do data? a when in was study CF even the two a that shared regulatory we of you from FDA these coming timeline? think there timelines? that you. could that MCS Just the mechanics the pending and think be there? How

Barbara White

Barbara. Thank for you Leland, this is again question. insightful. that Very

application, room is of current studies the we NDA thinking certainly to than for that in use would positive. should those one There to of day module indeed, application a is number be sections particularly some two, rather want Our submit X. the X module information, the CMC in same the – and certainly non-clinical the in and aspects and review safety both X the X, of non-clinical module module in

So, there efficient. help for be of is room overlap lots to

Leland Gershell

Great.

processed be, – So whether would all I Be delayed? or at would be we it guess, my CF question would meaningfully would negligible?

Barbara White

delay out other going said be getting of terms data We not need the after the done month CF we the and in think are There it’s things the SSc to waiting ready approximately we is quite come top-line. as data for manageable. for submission. Certainly, are data, expecting overall substantially CF a NDA the that to

Leland Gershell

taking Thank very Great. the much Okay. questions. you for

Operator

of question proceed Please question. is your BTIG. The Dae Ha Gon from with next

Dae Gon Ha

Great. well. Hope questions COVID-XX. end you from the are our for guys my well as and taking Thanks progress congrats on despite all all staying

once then, presenting up OLE, to on CRISS and as, also here, just of So critical can a expected I will but question, scores on at data? since expect, ACR about recognizing any ACR just calculation. data beat following both an a well as earlier we for this that from RESOLVE for horse you much talked couple And guess, also me, can how what report expect plays much mRSS and thoughts are X component just Barbara, not dead how a OLE RESOLVE you X, wondering CF data disclosure we to Specifically, the be looking just or CRISS your materialize quarter? top-line that latest maybe data role when the in you again, what

the COVID-XX then what variability you had wondering how restrictions if if can And that kind given of strategies and implemented to follow-up. you strategy you or got a will. monitoring, has speak I’ve evolved Just minimize to of

Barbara White

Okay.

take. them only to them remember me going a time. Thanks at I both. doing Let and two am for try

lost already. I’ve think I one

mRSS. So, one about the score about let data a we’ve CRISS me with is Certainly, talked with driver mRSS of that. variability start the major ACR

score, and patients uniformly. thickening the selected of experts clear Trials thing augment live mRSS and and – did make improved The systemic mRSS the skin certainly had expect all we and with of for and reduce international who, we variability, was in of Consortium, to they an whether care the we directionally from in in it significant sclerosis the the more a the important The we had not studies. course is approach be train patient think investigators the patients and pass But the we will Clinical developed statistically involving did that improved certificates. them other not the this next the the of to And to changes of a There way them study. to clinical did, experience very large components extensive or them, all trained group the part, decrease Scleroderma conduct all, mRSS investigators nearly they same assessment score with do in correct actually the to the is score and baseline. increase of we I if first

we the it actually the and was There significant Next data. a variability. investigators. we if to We we needed monitored retrained queried

I scores in of are of data. undue data, not lot – blinded variability am looking don’t I mRSS unexpected kind the So, over anticipating

where that’s are we think I that. So, with

again, about question Dae ACR can? Now if the you CRISS, what’s - Gon, the first

Dae Gon Ha

top-line we CF? First data for expect was at report when X just question can looking what RESOLVE both you and

Barbara White

yes. Yes,

will information. That’s critical. course, of for both you safety them, So, get of always

You the disposition. will get

So, did know patients how what. many you’ll

SSc think you SSc, You primary event secondaries efficacy efficacy get, will endpoints And study, are and of – with study, you get the get for secondary will quite There and for the actual most is of few the perhaps as at I they exacerbations. not endpoints. CF pulmonary if the longer rate secondaries. the a the the will relevant

HAC, secondary ACR you’ll the and with CRISS, know our definition of the mRSS, sclerosis of know are with SCC, our you using by the by pulmonary know And Phase you’ll know we’ve know you’ll exacerbations done we that the done safety. will least time So, you’ll CF, definition. at top-line you’ll rate time systemic X, know primary

Dae Gon Ha

bit Got is fully DM, of in wondering you your a very endpoints data what DM primer now as from the give you. recognizing we it. a given if different. How overlap glean and was from a of And speak terms much. could skin can little quite And that you’ve last there assay? well that bit perhaps can on Thanks attributes. improvement if underlying I my data different to score. maybe total is, SID maybe significant enrolled you some to as are question us that then, also of just SSc Thank manifestations, that

Barbara White

it assessments reflects again, developed is the from do patients in is best is improvement these And experts. will also nature Dae best of to the assess of and score that physician from lung. and very are we assessing assessments, this of the overall you, global think there those is could overall there to into components CRISS. to and put are which improvements. assessment equivalent an of and dermatomyositis determine scleroderma weighted that dermatomyositis. the the degree weakness overall total these baseline skin case algorithm ones composite be the assessment assessed a are then, components and of Gon. from a extracellular and organ manifestations it for study. Yes, score for degree in are There the patient think would The similar that the mRSS baseline in read a its Thank sclerosis a are in involvement. the a looks way a And disease composite of global – improvement It through systemic you improvement experts in improvement The effects. number if by of of include holistically picking muscle treatment components is There assessments assessing to which the key

I’d be be that at the patient the nature some quite involvement should at given there that the actually key that organ actual physician a similar, looking global of any read measure all should there we So, and disability, the are components through. that’s score of that way think

Dae Gon Ha

look questions the data. the taking forward to for Thanks Great. and

Barbara White

you. Thank

Operator

Please with We have Roth more Elemer time for proceed your Capital. question Piros of one from question.

Elemer Piros

you morning. Good Yes. Thank questions. for taking my

Just a Barbara. couple,

But particular I the there there CF is a in why So, question label no asked before. this reason I is extension don’t open think trial?

Barbara White

is at that are do there appropriate not they this And would that Elemer. first Hi, their point, thing feeling Yes, is Fibrosis their an at Barbara. perhaps, very experienced. leadership extensively be was and This with of time. worked that we to all, the Foundation and Cystic

That’s on follow And guidance really so, their one. we the reason. that

think that’s it. I

Elemer Piros

Okay.

can of trial the you. be Thank a you Could us in Scleroderma XX-weeks. on that other Okay. CF time be XX-week is different would of events tell one differently, the you. these I and at is they And them versus the the over handled imagine data trial collection missing observation since treated please methodologies Thank periods? would how

Barbara White

Sure.

let me CF. with all, of first So, start

first the exacerbations. rate that’s even you as and that, outcome also outcome pulmonary So, missing we on there little secondary of the very that collected that’s have is, primary know, pulmonary And remotely. data exacerbations of

essentially So, one. that first impact all, COVID-XX there was on of no

So, there going isn’t to that primary we anything endpoint. special do to need for are

study number is handled will ordinarily a missing will in end, done. handling other in and primary throughout be data mean, it was sensitivity will the lot and of there the And be the as said, handling done intent ways our initial our point. way patients the and in a at of LOCF, I of at missing patients missing data standard I other SSc, COVID-XX-only wasn’t to as that patients a the this in wasn’t approach lot or this that’s data analysis be handle it For by

the that unusual path. is in because Elemer think, it there We’ll don’t patients anything of I analysis pull are sensitivity our except with few and particularly So, missing COVID-XX. a that for with do LOCF

Elemer Piros

you Great. Barbara. thank so Well, much,

Operator

you. Thank

today’s webcast. have our and reached Ladies of that Session. the and concludes teleconference gentlemen, Question-And-Answer end We

You participation. your Thank and day. you for have may this a lines wonderful at disconnect time your

Corbus Pharmaceuticals (CRBP) 6 Aug 202020 Q2 Earnings call transcript